Menopausal women
Conditions
Interventions
Group 1 Prevenox (Experimental): 2 tablets of Prevenox of 5 mg daily by oral route, one taken with lunch and the other with dinner during 6 months.
Group 2 Placebo (Control): 2 placebo tablets daily b
Sponsors
National Centre for Scientific Research (CNIC)
Eligibility
Sex/Gender
Female
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: The sample will consist of women = 35 years old, who agree to participate in the study by signing their informed consent.
Exclusion criteria
Exclusion criteria: 1. Age under 35 years 2. Menopause 3. Diagnosed neoplasms 4. Decompensated chronic non-communicable diseases 5. Surgery within the last 3 months 6. Psychiatric disorders 7. Renal and/or hepatic insufficiency 8. Any other special condition that, in the physician's judgment, puts their health and life at risk during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C (Value measured in mmol/L).Measurement time: At baseline, 3 months and 6 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Total Cholesterol (Value measured in mmol/L).Measurement time: At baseline, 3 months and 6 months of treatment 2. HDL-C (Value measured in mmol/L).Measurement time: At baseline, 3 months and 6 months of treatment | — |
Countries
Cuba
Contacts
Public ContactDaysi Navarro Despaigne
National Institute of Endocrinology
Outcome results
None listed